RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

Core Insights - RedHill Biopharma Ltd. supports an independent medical education grant for a new two-part H. Pylori Continuing Medical Education (CME) program aimed at enhancing clinical knowledge and improving patient outcomes [1][3] - H. pylori is a significant health concern, classified as a Group 1 carcinogen by WHO, affecting nearly 50% of the global population and representing a billion-dollar market opportunity [1][5] - Talicia® is highlighted as the leading branded therapy for H. pylori, being the only FDA-approved all-in-one, low-dose rifabutin-based treatment [1][6] Company Overview - RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [18] - The company promotes Talicia for the treatment of H. pylori infection in adults and plans to submit a Marketing Authorisation Application (MAA) for Talicia in the UK [6][18] H. Pylori Infection Insights - H. pylori infection affects approximately 50% of the global adult population and is the strongest known risk factor for gastric cancer, causing 70% to 90% of cases [5][7] - The infection is also a major risk factor for peptic ulcer disease, with eradication becoming increasingly difficult due to high antibiotic resistance [7][8] CME Program Details - The CME program consists of two parts: - Part 1: A livestreamed expert panel on May 6, 2025, focusing on antibiotic resistance and guideline-directed therapies [3][4] - Part 2: An interactive online discussion scheduled for June 2025, addressing challenges in H. pylori diagnosis and treatment [4][5] Talicia Overview - Talicia is a fixed-dose, all-in-one oral capsule combining amoxicillin, rifabutin, and omeprazole, approved by the FDA in November 2019 [8][9] - The drug has received eight years of U.S. market exclusivity and is protected by patents extending until 2034 [8][18]